Trials / Terminated
TerminatedNCT02504619
Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies
Allogeneic Stem Cell Transplantation of CordIn™, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Gamida Cell ltd · Industry
- Sex
- All
- Age
- 2 Years – 25 Years
- Healthy volunteers
- Not accepted
Summary
CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells. The overall study objectives are to evaluate the safety and efficacy of CordIn™.
Detailed description
CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells. The trial ends when the last patient completes their last visit. The overall study objectives are to evaluate the safety and efficacy of CordIn™: single ex-vivo expanded cord blood unit transplantation in patients with hemoglobinopathies (sickle cell disease or thalassemia major) following a preparative therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CordIn | CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells. |
Timeline
- Start date
- 2016-04-04
- Primary completion
- 2016-08-01
- Completion
- 2017-12-01
- First posted
- 2015-07-22
- Last updated
- 2019-06-26
- Results posted
- 2019-06-26
Locations
3 sites across 2 countries: United States, France
Source: ClinicalTrials.gov record NCT02504619. Inclusion in this directory is not an endorsement.